Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) submission for U.S. market clearance to detect codeine. The study enrolled 135 participants across three independent U.S. clinical sites and evaluated sensitivity, specificity, and accuracy in workplace screening environments. With all clinical data collection complete, the company is finalizing its submission package and targets filing with the FDA in the second half of 2026. Intelligent Bio Solutions Inc. operates in the medical technology industry, developing rapid, non-invasive drug testing solutions using fingerprint sweat analysis.
